SLG
WX

Stanley-Laman Group’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Stanley-Laman Group’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,239
Closed -$221K – 381
2015
Q2 		$221K Hold
5,239
– – 0.04% 275
2015
Q1 		$203K Buy
+5,239
New +$202K 0.04% 290
2014
Q2 		– Sell
-7,176
Closed -$265K – 307
2014
Q1 		$265K Hold
7,176
– – 0.05% 280
2013
Q4 		$275K Buy
+7,176
New +$227K 0.06% 181

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Stanley-Laman Group's WX Position: Q3 2015 in Review

Stanley-Laman Group sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q3 2015, closing a stake of 5,239 shares — an estimated $221K sold.

Stanley-Laman Group first reported a position in WX in Q4 2013 and held it in 4 quarters. The position peaked at $275K in Q4 2013. 151 funds tracked by Wall St. Rank hold WX as of Q3 2015.

  • Stanley-Laman Group reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q3 2015 after selling out during the quarter.
  • Stanley-Laman Group sold 5,239 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2015, an estimated $221K.
  • Stanley-Laman Group first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2013 and held it in 4 quarters.
  • Stanley-Laman Group's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $275K in Q4 2013.
  • 151 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2015.

Based on Stanley-Laman Group's 13F filing for Q3 2015, filed 3 Nov 2015.